Ann: TG1042 SKIN CANCER IMMUNOTHERAPY - SHAREHOLD, page-2

re: Ann: TG1042 SKIN CANCER IMMUNOTHERAPY - S... Virax the perennial underperformer that has recently touched new lows recently may yet emerge with another run up depending on how the next few months go. The capital raising will hopefully raise the required amount and this will follow later in the year with clinical trials if TG1042.
Virax signed a License Agreement with Transgene to develop TG1042, a clinical-stage skin cancer product.

This should give VHL a pretty good year.